Register Login
Register to leave comments
  • News bot Oct. 1, 2025, 9:50 p.m.

    📋 NEKTAR THERAPEUTICS (NKTR) - Clinical Trial Update

    Filing Date: 2022-05-23

    Accepted: 2022-05-23 09:20:27

    Event Type: Clinical Trial Update

    Event Details:

    Nektar Therapeutics (NKTR) Announces Clinical Trial Update Nektar Therapeutics (NKTR) provided an update on its clinical development programs. Clinical Development Highlights:
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process

    🔬 Clinical Development Pipeline (NEKTAR THERAPEUTICS):

    Product Type Development Stage Therapeutic Area Source
    Treatment of Physician's Choice (TPC) DRUG Phase PHASE3 Locally Recurrent Breast Cancer ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Pneumonia ClinicalTrials.gov
    Biopsy PROCEDURE Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Biospecimen Collection PROCEDURE Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Positron Emission Tomography PROCEDURE Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Computed Tomography PROCEDURE Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Lumbar Puncture PROCEDURE Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Bone Marrow Aspiration PROCEDURE Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Bone Marrow Biopsy PROCEDURE Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Multigated Acquisition Scan PROCEDURE Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Echocardiography PROCEDURE Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    X-Ray Imaging PROCEDURE Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Polymer-conjugated IL-15 Receptor Agonist NKTR-255 DRUG Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Lisocabtagene Maraleucel BIOLOGICAL Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Fludarabine DRUG Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Cyclophosphamide DRUG Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    C-TIL051 BIOLOGICAL Phase PHASE1 Metastatic Non Small Cell Lung Cancer ClinicalTrials.gov
    aerosolized vancomycin or gentamicin DRUG Phase PHASE2 Ventilator Associated Pneumonia ClinicalTrials.gov
    Amikacin (BAY41-6551) DRUG Phase PHASE2 Pneumonia ClinicalTrials.gov
    NKTT120 DRUG Phase PHASE1 Sickle Cell Disease ClinicalTrials.gov
    Amikacin inhalation solution (BAY41-6551) DRUG Phase PHASE2 Pneumonia ClinicalTrials.gov
    Etirinotecan pegol DRUG Phase PHASE2 Anaplastic Astrocytomas ClinicalTrials.gov
    Dronabinol MDI DRUG Phase PHASE2 Migraine With Aura ClinicalTrials.gov
    NKTR-102 DRUG Phase PHASE2 Tumor ClinicalTrials.gov
    50 mg/m2 NKTR 102 DRUG Phase PHASE1 Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment ClinicalTrials.gov
    120 mg/m2 NKTR 102 DRUG Phase PHASE1 Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment ClinicalTrials.gov
    145 mg/m2 NKTR 102 DRUG Phase PHASE1 Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment ClinicalTrials.gov
    Aerosolized Placebo DRUG Phase PHASE3 Pneumonia, Bacterial ClinicalTrials.gov
    Pharmacological Study OTHER Phase PHASE2 Recurrent Small Cell Lung Carcinoma ClinicalTrials.gov
    Pegylated Irinotecan DRUG Phase PHASE2 Recurrent Small Cell Lung Carcinoma ClinicalTrials.gov
    Laboratory Biomarker Analysis OTHER Phase PHASE2 Recurrent Small Cell Lung Carcinoma ClinicalTrials.gov
    Placebo to match NKTR-181 BID tablets DRUG Phase PHASE3 Low Back Pain ClinicalTrials.gov
    NKTR-181 BID tablets DRUG Phase PHASE3 Low Back Pain ClinicalTrials.gov
    NKTR-214 DRUG Phase PHASE1 Unspecified Adult Solid Tumor, Protocol Specific ClinicalTrials.gov
    Cetuximab DRUG Phase PHASE2 Tumor ClinicalTrials.gov
    NKTR-102 125 mg/m2 DRUG Phase PHASE2 Tumor ClinicalTrials.gov
    NKTR-102 100 mg/m2 DRUG Phase PHASE2 Tumor ClinicalTrials.gov
    NKTR-102 50 mg/m2 DRUG Phase PHASE2 Malignant Solid Tumor ClinicalTrials.gov
    NKTR-102 95 mg/m2 DRUG Phase PHASE2 Malignant Solid Tumor ClinicalTrials.gov
    NKTR-102 120 mg/m2 DRUG Phase PHASE2 Malignant Solid Tumor ClinicalTrials.gov
    NKTR-102 145 mg/m2 DRUG Phase PHASE2 Malignant Solid Tumor ClinicalTrials.gov
    Oxycodone IR DRUG Phase PHASE1 Moderate to Severe Chronic Pain ClinicalTrials.gov
    NKTR-181 DRUG Phase PHASE1 Moderate to Severe Chronic Pain ClinicalTrials.gov
    ⁸⁹Zr-Df-IAB22M2C DRUG Phase PHASE1 Metastatic Melanoma ClinicalTrials.gov
    Nivolumab BIOLOGICAL Phase PHASE1 Metastatic Melanoma ClinicalTrials.gov
    Bempegaldesleukin (NKTR-214) BIOLOGICAL Phase PHASE1 Metastatic Melanoma ClinicalTrials.gov
    NKTR-102 q21d DRUG Phase PHASE2 Tumor ClinicalTrials.gov
    NKTR-102 q14d DRUG Phase PHASE2 Tumor ClinicalTrials.gov
    irinotecan DRUG Phase PHASE2 Colorectal Cancer ClinicalTrials.gov
    Atezolizumab DRUG Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    Pemetrexed DRUG Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    Paclitaxel DRUG Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    Nab paclitaxel DRUG Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    Carboplatin DRUG Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    Cisplatin DRUG Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    Pembrolizumab DRUG Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    Bempegaldesleukin DRUG Phase PHASE1 Locally Advanced or Metastatic Solid Tumours ClinicalTrials.gov
    VB10.NEO BIOLOGICAL Phase PHASE1 Locally Advanced or Metastatic Solid Tumours ClinicalTrials.gov
    LY3471851 DRUG Phase PHASE2 Colitis, Ulcerative ClinicalTrials.gov
    NKTR-262 DRUG Phase PHASE1 Melanoma ClinicalTrials.gov
    Nab-paclitaxel DRUG Phase PHASE3 Metastasis ClinicalTrials.gov
    Docetaxel DRUG Phase PHASE3 Metastasis ClinicalTrials.gov
    Gemcitabine DRUG Phase PHASE3 Metastasis ClinicalTrials.gov
    Vinorelbine DRUG Phase PHASE3 Metastasis ClinicalTrials.gov
    Ixabepilone DRUG Phase PHASE3 Metastasis ClinicalTrials.gov
    Eribulin DRUG Phase PHASE3 Metastasis ClinicalTrials.gov
    Daratumumab DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Rituximab DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    NKTR-255 Q21 DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    NKTR-255 DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab DRUG Phase PHASE1 Melanoma ClinicalTrials.gov
    Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab DRUG Phase PHASE1 Melanoma ClinicalTrials.gov
    Dose Expansion Doublet: Combination of NKTR-214 + nivolumab DRUG Phase PHASE1 Melanoma ClinicalTrials.gov
    Dose Escalation Doublet: Combination of NKTR-214 + nivolumab DRUG Phase PHASE1 Melanoma ClinicalTrials.gov
    cabozantinib DRUG Phase PHASE3 Renal Cell Carcinoma ClinicalTrials.gov
    sunitinib DRUG Phase PHASE3 Renal Cell Carcinoma ClinicalTrials.gov
    Palliative Radiation RADIATION Phase PHASE2 Head and Neck Cancer ClinicalTrials.gov
    anti-PD-1 therapy DRUG Phase PHASE2 Head and Neck Cancer ClinicalTrials.gov
    Standard of Care DRUG Phase PHASE1 Covid-19 ClinicalTrials.gov
    Levocetirizine DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Durvalumab DRUG Phase PHASE2 Lung Cancer ClinicalTrials.gov
    Placebo Comparator OTHER Phase PHASE2 Non-Hodgkin Lymphoma ClinicalTrials.gov
    NKTR-255 at 3.0/6.0 μg/kg DRUG Phase PHASE2 Non-Hodgkin Lymphoma ClinicalTrials.gov
    NKTR-255 at 3.0 μg/kg DRUG Phase PHASE2 Non-Hodgkin Lymphoma ClinicalTrials.gov
    NKTR-255 at 1.5 µg/kg DRUG Phase PHASE2 Non-Hodgkin Lymphoma ClinicalTrials.gov
    Rezpegaldesleukin DRUG Phase PHASE2 Moderate to Severe Atopic Dermatitis ClinicalTrials.gov
    M6223 DRUG Phase PHASE2 Locally Advanced or Metastatic Urothelial Carcinoma ClinicalTrials.gov
    Sacituzumab Govitecan DRUG Phase PHASE2 Locally Advanced or Metastatic Urothelial Carcinoma ClinicalTrials.gov
    Avelumab DRUG Phase PHASE2 Locally Advanced or Metastatic Urothelial Carcinoma ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Nektar Therapeutics
    • CIK: 0000906709
    • Ticker Symbol: NKTR
    • Period End Date: 2022-05-19
    • Document Type: 8-K

Search

News categories